Percardia Inc.

Once one of the most promising of the start-ups targeting vulnerable plaque, Volcano has found a formula that should make the company a winner—whether vulnerable ever emerges as a major play or not. B

Italy has become the most favored European point-of-entry for many US device start-ups. NGC is responding to hospitals' needs to shift the risk burden in order to maintain the pace of cardiovascular i

Medical device investors are still looking for opportunities in cardiac surgery, but the rules of the game have changed. By Stephen Levin If Mark Twain were a doctor today, no doubt he'd be a cardioth

Heightened public scrutiny of hospital buying groups is causing leading GPOs to amend their policies and practices. The good news: more transparency in GPO decisions. But is it enough? by David Cassak